Agencies agree to purchase investigational antiviral if authorized by FDA
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced today.
If authorized, the federal government will allocate the drug (molnupiravir) to states and territories. Health care providers would order the drug directly from the distributor within those allocations, HHS said.
Related News Articles
Headline
The Senate Appropriations Committee Nov. 17 released its version of the fiscal year 2027 appropriations bill for the departments of Labor, Health and Human…
Headline
In comments provided Nov. 16 to majority and minority leaders of the House and Senate, the AHA requested Congress to act on key priorities for hospitals and…
Headline
The Centers for Medicare & Medicaid Services Nov. 9 announced allocations for the second year of the Rural Health Transformation Program, which will award…
Headline
The Centers for Medicare & Medicaid Services Nov. 4 released its calendar year 2027 final rule for the physician fee schedule. As required by law, CMS will…
Headline
The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a…
Headline
The U.S. District Court for the District of Massachusetts yesterday ruled in favor of 25 states and the District of Columbia to vacate the Centers for Medicare…